high5immunology.tv | IBD | UEG Week 2023

Targeting efficacy discussions

QUASAR, LUCENT-1/2, INSPIRE

UEG 2023

Is IL-23 blockade breaking the ceiling in UC?

M. Allez, G. Rogler, D. Laharie, A. Moschen, A. Dignass, S. Schreiber

SEQUENCE

UEG 2023

The place of IL-23 blockers in crohn's disease

M. Allez, G. Rogler, D. Laharie, A. Moschen, A. Dignass, S. Schreiber

SELECTION, U-ACTIVATE

UEG 2023

Benefit of JAKies in ulcerative colitis

M. Allez, G. Rogler, D. Laharie, A. Moschen, A. Dignass, S. Schreiber

ARTEMIS-UC, ARTEMIS-UC

UEG 2023

Anti-TL1A: on the way to precision medicine?

M. Allez, G. Rogler, D. Laharie, A. Moschen, A. Dignass, S. Schreiber

ARTEMIS-UC

UEG 2023

New kids on the block - next generation therapeutics

A. Dignass, S. Schreiber, A. Armuzzi, S. Vermeire, S. Danese, M. Fantini, F. Magro

DIVERSITY1, U-ENDURE

UEG 2023

Do different JAKies have different profiles?

M. Allez, G. Rogler, D. Laharie, A. Moschen, A. Dignass, S. Schreiber

Targeting efficacy IBD 100 sec – ENG

QUASAR

UEG 2023

Guselkumab readily controls symptoms in patients…

Massimo Fantini, MD

UEG 2023

News on IBD therapy!

Alessandro Armuzzi, MD

QUASAR

UEG 2023

A lot of noise about IL-23 blockers - 1

Axel Dignaß, MD

True North, ELEVATE UC 12 & 52

UEG 2023

Key topic S1P-modulation

Axel Dignaß, MD

DIVERSITY1, U-ENDURE

UEG 2023

Update on JAKies

Axel Dignaß, MD

SEQUENCE, INSPIRE

UEG 2023

A lot of noise about IL-23 blockers - 2

Axel Dignaß, MD

UEG 2023

Small molecules in IBD

Alessandro Armuzzi, MD

Targeting efficacy IBD 100 sec – multi language

QUASAR, SEQUENCE, INSPIRE

UEG 2023

Viel Wirbel um die Interleukin-23-Blockade

Axel Dignaß, MD

DIVERSITY1, U-ENDURE

UEG 2023

Update zu JAK-Inhibitoren

Axel Dignaß, MD

QUASAR

UEG 2023

Rapido controllo dei sintomi nei pazienti affetti da…

Massimo Fantini, MD

True North, ELEVATE UC 12 & 52

UEG 2023

S1P-Modulatoren im Fokus

Axel Dignaß, MD

UEG 2023

Small molecules nelle IBD

Alessandro Armuzzi, MD

UEG 2023

Novità nelle terapie per le IBD!

Alessandro Armuzzi, MD

Targeting efficacy CD 100 sec – ENG

DIVERSITY1

UEG 2023

Phase III results of filgotinib in CD

Séverine Vermeire, MD

SEQUENCE

UEG 2023

Risankizumab vs. ustekinumab in CD: The SEQUENCE trial

Fernando Magro, MD

SEQUENCE

UEG 2023

Head-to-head efficacy comparison of risankizumab vs…

Massimo Fantini, MD

OL maintenance Phase 2b

UEG 2023

Long-term efficacy of obefazimod in UC

Séverine Vermeire, MD

SEQUENCE

UEG 2023

First positive head-to-head trial in CD

James Lindsay, MD

UEG 2023

Ustekinumab vs. adamlimumab for prevention of early…

Gerassimos Mantzaris, MD

UEG 2023

High IL23 expression at baseline is predictive of…

Massimo Fantini, MD

LUCENT-1/2

UEG 2023

Mirikizumab reaches similar therapeutic outcomes in UC…

Massimo Fantini, MD

Targeting efficacy CD 100 sec – multi language

UEG 2023

Elevati livelli basali di IL23 predicono la remissione…

Massimo Fantini, MD

LUCENT-1/2

UEG 2023

Mirikizumab resulta efficace in RCU a prescindere dalla…

Massimo Fantini, MD

UEG 2023

Ustekinumab vs. adalimumab για την πρόληψη της πρώιμης…

Gerassimos Mantzaris, MD

SEQUENCE

UEG 2023

Comparazione testa a testa di Risankizumab e…

Massimo Fantini, MD

Targeting efficacy UC 100 sec – ENG

ELEVATE UC 12 & 52

UEG 2023

Fast-acting etrasimod in UC

James Lindsay, MD

LUCENT-1/2/3

UEG 2023

Longterm endohistological response induced by…

Fernando Magro, MD

ELEVATE UC 12 & 52

UEG 2023

Disease clearance induced by etrasimod and relationship…

Fernando Magro, MD

INSPIRE

UEG 2023

Another p19 antibody in UC

Peter Irving, MD

INSPIRE

UEG 2023

Risankizumab in UC

James Lindsay, MD

ARTEMIS-UC

UEG 2023

PRA023 - a new anti-TL1A antibody in moderate to severe…

Silvio Danese, MD

True North

UEG 2023

Disease severity affects response in ozanimod treated…

Peter Irving, MD

Lucent-1/2

UEG 2023

Mirikizumab in moderate to severe UC

Silvio Danese, MD

Targeting efficacy UC 100 sec – multi language

ARTEMIS-UC

UEG 2023

PRA023 - un nuovo anticorpo anti-TL1A nella colite…

Silvio Danese, MD

Lucent-1/3

UEG 2023

Mirikizumab nella colite ulcerosa da moderata a grave

Silvio Danese, MD

DIVERSITY1

UEG 2023

Fase III resultaten met filgotinib in CD

Séverine Vermeire, MD

OL maintenance Phase 2b

UEG 2023

Lange termijn efficaciteit van Obefazimod UC

Séverine Vermeire, MD

Therapeutic concepts discussions

VARSITY

UEG 2023

The quest for perfect predictors of response - AI…

G. Mantzaris, P. Eder, J. Lindsay, P. Irving, A. Dignaß, S. Schreiber

PORCSE, SPICY TRIAL, KoCoRICCO

UEG 2023

How to prevent post-operative recurrence in CD?

G. Mantzaris, P. Eder, J. Lindsay, P. Irving, A. Dignaß, S. Schreiber

VARSITY

UEG 2023

Combined endpoints - composition and implementation in…

A. Dignass, S. Schreiber, A. Armuzzi, S. Vermeire, S. Danese, M. Fantini, F. Magro

CURE GETECCU (EXIT)

UEG 2023

Can we stop biologics?

G. Mantzaris, P. Eder, J. Lindsay, P. Irving, A. Dignaß, S. Schreiber

POWER

UEG 2023

Efficacy and safety of switching iv vs. sc

G. Mantzaris, P. Eder, J. Lindsay, P. Irving, A. Dignaß, S. Schreiber

True North, ELEVATE UC 12 & 52

UEG 2023

S1P modulation: ozanimod vs. etrasimod

G. Mantzaris, P. Eder, J. Lindsay, P. Irving, A. Dignaß, S. Schreiber

Therapeutic concepts IBD 100 sec – ENG

UEG 2023

Navigating in the therapeutic IBD landscape

Séverine Vermeire, MD

UEG 2023

Infliximab sc application associated with better…

Gerhard Rogler, MD

UEG 2023

To switch or not to switch in IBD - new real-life data…

Piotr Eder, MD

GETECCU (EXIT)

UEG 2023

More evidence that anti TNF-withdrawel increases…

Peter Irving, MD

Therapeutic concepts IBD 100 sec – multi language

UEG 2023

Navigeren in het therapeutisch landschap in IBD

Séverine Vermeire, MD

UEG 2023

Infliximab sc führt zu besseren Langzeitergebnissen

Gerhard Rogler, MD

UEG 2023

Konwersja do terapii podskórnej NZJ - nowe dane typu…

Piotr Eder, MD

Therapeutic concepts CD 100 sec – ENG

CURE

UEG 2023

Stopping adalimumab in early CD?

David Laharie, MD

SEQUENCE

UEG 2023

SEQUENCE study

Stefan Schreiber, MD

CURE

UEG 2023

Did GETAID close the window of opportunity?

Gerhard Rogler, MD

PORCSE

UEG 2023

Postoperative recurrence in Crohn's disease after…

Piotr Eder, MD

KoCoRICCO, SPICY TRIAL

UEG 2023

Surgical news: prevention of post-operative recurrence…

Matthieu Allez, MD

PORCSE

UEG 2023

Medical news: Which treatment and when?

Matthieu Allez, MD

Therapeutic concepts CD 100 sec – multi language

PORCSE

UEG 2023

Nawroty pooperacyjne u pacjentów z chorobą…

Piotr Eder, MD

SEQUENCE

UEG 2023

SEQUENCE Studie

Stefan Schreiber, MD

CURE

UEG 2023

Peut-on arrêter l'adalimumab dans la maladie de Crohn…

David Laharie, MD

PORCSE

UEG 2023

Actualités médicales: Quel traitement et quand?

Matthieu Allez, MD

KoCoRICCO, SPICY TRIAL

UEG 2023

Nouveauté sur la chirurgie: Prévention de la récidive…

Matthieu Allez, MD

CURE

UEG 2023

Hat GETAID das "Window of opportunity" geschlossen?

Gerhard Rogler, MD

Therapeutic concepts UC 100 sec – ENG

UEG 2023

Which maintenance therapy in AS-CU is responding to…

David Laharie, MD

ARTEMIS-UC

UEG 2023

The anti TL1A/Dx-toolbox package: Are we entering…

Alexander Moschen, MD

Therapeutic concepts UC 100 sec – multi language

UEG 2023

Quel traitement d'entretien dans l'AS-CU répondant aux…

David Laharie, MD

ARTEMIS-UC

UEG 2023

Anti-TL1A im Paket mit der Dx-Toolbox - Einstieg in die…

Alexander Moschen, MD

Treatment goals 100 sec – ENG

VARSITY

UEG 2023

Comprehensive disease control - a new currency

Stefan Schreiber, MD

Treatment goals 100 sec – multi language

VARSITY

UEG 2023

Comprehensive disease control - eine neue Währung

Stefan Schreiber, MD

Targeting safety discussions

LUCENT-1/2, QUASAR, TORUS

UEG 2023

What do we know about multi-failures?

A. Dignass, S. Schreiber, A. Armuzzi, S. Vermeire, S. Danese, M. Fantini, F. Magro

OCTAV,E U-ACTIVATE, DIVERSITY1, SELECTION

UEG 2023

New safety signals on JAKies?

A. Dignass, S. Schreiber, A. Armuzzi, S. Vermeire, S. Danese, M. Fantini, F. Magro

ELEVATE UC 12 & 52

UEG 2023

S1P modulation: effective and safe?

A. Dignass, S. Schreiber, A. Armuzzi, S. Vermeire, S. Danese, M. Fantini, F. Magro

Targeting safety 100 sec – ENG

UEG 2023

Do JAK inhibitors cause acne?

Gerassimos Mantzaris, MD

GETECCU (EXIT)

UEG 2023

Is it feasible to stop effective anti-TNF therapy in…

Piotr Eder, MD

ADVANCE, MOTIVATE, FORTIFY

UEG 2023

Is risankinumab effective for EIMs of IBD?

Gerassimos Mantzaris, MD

ADVANCE/MOTIVATE post-hoc

UEG 2023

Effective control of EIMs in CD patients treated with…

Massimo Fantini, MD

Targeting safety 100 sec – multi language

GETECCU (EXIT)

UEG 2023

Czy możemy bezpiecznie przerwać skuteczną terapię…

Piotr Eder, MD

UEG 2023

Προκαλούν οι αναστολείς των JAK ακμή;

Gerassimos Mantzaris, MD

ADVANCE, MOTIVATE, FORTIFY

UEG 2023

Είναι το risankisumab αποτελεσματικό για τη θεραπεία…

Gerassimos Mantzaris, MD

ADVANCE/MOTIVATE post-hoc

UEG 2023

Efficace controllo delle MEI in pazienti affetti da MDC…

Massimo Fantini, MD

Basic science 100 sec – ENG

UEG 2023

Neutrophil fibroblast crosstalk is driving fribrosis in…

Alexander Moschen, MD

UEG 2023

Morphologic alteration of mesentric lymph nodes under…

Alexander Moschen, MD

Basic science 100 sec – multi language

UEG 2023

Neutrophile Fibroblasteninteraktion treibt die Fibrose…

Alexander Moschen, MD

UEG 2023

Morphologische Veränderung mesenterialer Lymphknoten…

Alexander Moschen, MD